1. Nanomedicine

Category Archives: Nanomedicine

Combining antibodies, iron nanoparticles and magnets steers stem cells to injured organs

Posted on by

Study published in Nature Communications details targeted nanomedicine therapy to regenerate heart muscle injured by heart attack

LOS ANGELES Researchers at the Cedars-Sinai Heart Institute infused antibody-studded iron nanoparticles into the bloodstream to treat heart attack damage. The combined nanoparticle enabled precise localization of the body's own stem cells to the injured heart muscle.

The study, which focused on laboratory rats, was published today in the online peer reviewed journal Nature Communications. The study addresses a central challenge in stem cell therapeutics: how to achieve targeted interactions between stem cells and injured cells.

Although stem cells can be a potent weapon in the fight against certain diseases, simply infusing a patient with stem cells is no guarantee the stem cells will be able to travel to the injured area and work collaboratively with the cells already there.

"Infusing stem cells into arteries in order to regenerate injured heart muscle can be inefficient," said Eduardo Marbn, MD, PhD, director of the Cedars-Sinai Heart Institute, who led the research team. "Because the heart is continuously pumping, the stem cells can be pushed out of the heart chamber before they even get a chance to begin to heal the injury."

In an attempt to target healing stem cells to the site of the injury, researchers coated iron nanoparticles with two kinds of antibodies, proteins that recognize and bind specifically to stem cells and to injured cells in the body. After the nanoparticles were infused into the bloodstream, they successfully tracked to the injured area and initiated healing.

"The result is a kind of molecular matchmaking," Marbn said. "Through magnetic resonance imaging, we were able to see the iron-tagged cells traveling to the site of injury where the healing could begin. Furthermore, targeting was enhanced even further by placing a magnet above the injured heart."

The Cedars-Sinai Heart Institute has been at the forefront of developing investigational stem cell treatments for heart attack patients. In 2009, Marbn and his team completed the world's first procedure in which a patient's own heart tissue was used to grow specialized heart stem cells. The specialized cells were then injected back into the patient's heart in an effort to repair and regrow healthy muscle in a heart that had been injured by a heart attack. Results, published in The Lancet in 2012, showed that one year after receiving the stem cell treatment, heart attack patients demonstrated a significant reduction in the size of the scar left on the heart muscle.

Earlier this year, Heart Institute researchers began a new study, called ALLSTAR, in which heart attack patients are being infused with allogeneic stem cells, which are derived from donor-quality hearts.

The process to grow cardiac-derived stem cells was developed by Dr. Marbn when he was on the faculty of Johns Hopkins University. Johns Hopkins has filed for a patent on that intellectual property and has licensed it to Capricor, a company in which Cedars-Sinai and Dr. Marbn have a financial interest. Capricor is providing funds for the ALLSTAR clinical trial at Cedars-Sinai. Recently, the Heart Institute opened the nation's first Regenerative Medicine Clinic, designed to match heart and vascular disease patients with appropriate stem cell clinical trials being conducted at Cedars-Sinai and other institutions.

Excerpt from:
Combining antibodies, iron nanoparticles and magnets steers stem cells to injured organs

IBM’s ‘Ninja Particles’ could stop the rise of superbugs

Posted on by

IBM Research's Jim Hedrick has a great job. His work on polymers -- those repeating chains of macromolecules that make up most things in our world, like the computer or phone you're reading this on -- has led to the creation of substances with Marvel Comics-worthy descriptors. There's the self-healing, Wolverine-like substance that arose from a recycled water bottle and something called "ninja particles" that'll advance the reality of nanomedicine. Both discoveries will inevitably make their way into consumer products in the near future, but it's his team's progress on nanomedicine that Hedrick discussed during my visit to IBM Research's sprawling Almaden lab in San Jose, California.

The inspiration for IBM's foray into nanomedicine is twofold: our growing resistance to antibiotics and the incidence of medical-implant rejection by the human body. With this in mind, Hedrick and his team, leveraging IBM's background in semiconductor research, developed synthetic polymers that mimic the immune system. Using a simple charge, these resultant polymers are capable of hunting down and clinging to specific microbes throughout the body. And, once attached, cause those microbes to rupture as if they'd been hit by an explosive shuriken (or ninja star) -- hence, the name.

Of course, anyone who's seen Innerspace knows there's a certain danger to injecting foreign objects into your body. But Hedrick says we have nothing to worry about. The ninja particles won't pass into other parts of the body. They're also proven to have a low toxicity and, best of all, won't engender a new wave of resistant pathogens (read: superbugs). So when will see the practical fruits of IBM's research? Well, Hedrick tells us the company's already in talks with various partners to apply this nanotech to our modern world in anything from medicine to the deodorant we use daily to the detergents we use to wash our clothes and kitchenware. And that future's not too far off, either -- Hedrick believes we could begin to see these ninja particle-infused products hit retail within a decade's time.

Watch Hedrick explain how IBM's research into ninja particles can help revolutionize the health care industry.

Stay tuned for part three of our inside look at IBM's Almaden research facility.

[Image credit: Laguna Design/Getty]

Read more from the original source:
IBM's 'Ninja Particles' could stop the rise of superbugs

Fantastic voyage in nanomedicine takes us into realm of science fiction

Posted on by

In 1966, scientists made a huge breakthrough in nanomedicine. They found they could miniaturise a submarine and its crew and inject it into a patients bloodstream. The sub then wound its way through the patients body till it reached the brain, where the crew could then destroy a blood clot using laser guns.

Of course, this was pure science fiction. It was the plot of the movie Fantastic Voyage, a phantasmagorical thriller in which the intrepid crew of the Proteus had just one hour to save the life of a top scientist, while avoiding such dangers as voracious white blood cells, lymph nodes and enemy spies. As a kid, I was enthralled by the film: secret agents, giant man-eating antibodies, and Raquel Welch as a sexy scientist it was a boys own fantasy.

In real life, were a long way from shrinking people and sending them inside someones body to carry out surgical procedures. But we are able to use nanoparticles as intravenous couriers to deliver drugs to specific parts of the body, or to sneak tiny Trojan horses into cancerous cells to destroy them from the inside.

In Ireland, pioneering research into nanomed is being done at Crann, the Centre for Research on Adaptive Nanostructures and Nanodevices, Trinitys largest research institute.

Two leaders in the field of nanomedicine, Prof Yuri Volkov, chair of molecular and translational medicine and director of research at the TCD School of Medicine, and Prof Adriele Prina-Mello, are working together to develop ways to accurately attack illness using nanomaterials. Prof Volkov, whose team was working with cells and molecules and signalling processes, joined up with Prof Prina-Mello, whose team were perfecting nanomaterials.

It was the result of an opening up of a large-scale interdisciplinary collaboration within the college. And it merged into something where you can apply those nanoparticles for treatment and benefit in the biomedical setting. Thats how its developed, says Prof Volkov.

Prof Volkov also co-ordinates a Europe-wide consortium called Namdiatream, which co-ordinates expertise from around the EU to create nanotech toolkits for early diagnosis and treatment of cancer.

Nanomedicine is a relatively young science, but already it is making great strides, and, says Prof Volkov, nanoparticles are already being used to target disease at the cellular and even molecular level.

We are dealing with very small structures which are positioned in between the individual atoms, and small biological molecules such as proteins, says Prof Volkov.

Were talking about yokes a mere handful of atoms thick you wouldnt be using a tweezers. So how do you manipulate nanomaterials, and how can you even see whats going on at that level?

Here is the original post:
Fantastic voyage in nanomedicine takes us into realm of science fiction

New knowledge of cannabis paves way for drug development

Posted on by

About 40% of all medicines used today work through the so-called "G protein-coupled receptors." These receptors react to changes in the cell environment, for example, to increased amounts of chemicals like cannabis, adrenaline or the medications we take and are therefore of paramount importance to the pharmaceutical industry.

"There is a lot of attention on research into "G protein-coupled receptors," because they have a key roll in recognizing and binding different substances. Our new method is of interest to the industry because it can contribute to faster and cheaper drug development," explains Professor Dimitrios Stamou, who heads the Nanomedicine research group at the Nano-Science Center, where the method has been developed. The new method is described in a publication at the esteemed scientific journal Nature Methods.

Cheaper to test and develop medicine

The new method will reduce dramatically the use of precious membrane protein samples. Traditionally, you test a medicinal substance by using small drops of a sample containing the protein that the medicine binds to. If you look closely enough however, each drop is composed of thousands of billions of small nano-containers containing the isolated proteins. Until now, it has been assumed that all of these nano-containers are identical. But it turns out this is not the case and that is why researchers can use a billion times smaller samples for testing drug candidates than hitherto.

"We have discovered that each one of the countless nano-containers is unique. Our method allows us to collect information about each individual nano-container. We can use this information to construct high-throughput screens, where you can, for example, test how medicinal drugs bind G protein-coupled receptors," explains Signe Mathiasen, who is first author of the paper describing the screening method in Nature Methods. Signe Mathiasen has worked on developing a screening method over the last four years at the University of Copenhagen, where she wrote her PhD thesis research project under the supervision of Professor Stamou.

Story Source:

The above story is based on materials provided by Faculty of Science - University of Copenhagen. Note: Materials may be edited for content and length.

Here is the original post:
New knowledge of cannabis paves way for drug development

Training the next generation of cancer nanomedicine scientists

Posted on by

PUBLIC RELEASE DATE:

18-Aug-2014

Contact: Casey Bayer c.bayer@neu.edu 617-373-2592 Northeastern University

Northeastern University has received a five-year, $1.15 million grant from the National Institutes of Health's National Cancer Institute to train the next generation of cancer nanomedicine scientists and clinicians through a unique experiential learning program.

The centerpiece of the new program, which is called "CaNCURE: Cancer Nanomedicine Co-ops for Undergraduate Research Experiences," is a unique partnership between Northeastern and the Initiative to Eliminate Cancer Disparities at the Dana-Farber/Harvard Cancer Center. The DF/HCC is the world's largest comprehensive cancer center, bringing together the research efforts of its seven member institutions, comprising Beth Israel Deaconess Medical Center, Boston Children's Hospital, Brigham and Women's Hospital, Massachusetts General Hospital, Dana-Farber Cancer Institute, Harvard Medical School, and the Harvard School of Public Health. For more than a decade, the IECDamong the nation's first integrated, inter-institutional programs focused on eliminating cancer disparitieshas offered programming to address the complexities of cancer disparities, including training students, enhancing research, and facilitating access to underserved populations.

"Nanotechnology is leading to breakthroughs in diagnosis and therapy of many diseases, particularly cancer, leading to the new discipline of cancer nanomedicine," said principal investigator Srinivas Sridhar, Northeastern's Arts and Science Distinguished Professor of Physics, Bioengineering, and Chemical Engineering, and the director of the university's IGERT Nanomedicine Science and Technology program. "Advances in the field are beginning to have revolutionary impact on healthcare."

Over the next five years, a total of 75 undergraduate students will receive training to study and conduct cancer nanomedicine research in the laboratories of 35 leading scientists at Northeastern and DF/HCC. These six-month co-op experiences, facilitated through Northeastern's co-op office, will provide students in majors ranging from biomedical physics to chemical engineering with hands-on research experience and one-on-one mentoring from the leading researchers in cancer nanomedicine at these partner institutions.

"These mentors represent some of the world's best scientists in cancer nanomedicine research," Sridhar explained, noting that the undergraduate researchers will also have the opportunity to collaborate with their postdocs and graduate students. "We are tapping into an unprecedented resource of talent and expertise for teaching and the students' learning environment is going to be absolutely outstanding."

Sridhar, who expects to enroll the program's initial cohort of students this fall, has placed an emphasis on attracting young scientists from underrepresented minority groups. "Our goals are well aligned with that of NCI, which wants to ensure that segments of the population that are underrepresented in the scientific and healthcare professions have access to opportunities in research and professional development," he said.

All enrollees will participate in specialized workshops, conferences, and bi-monthly seminars featuring cancer nanomedicine experts. At the conclusion of the yearlong program, each student will give a presentation of his or her work.

See the article here:
Training the next generation of cancer nanomedicine scientists

DGAP-News: MagForce AG: Successful final closing of a growth financing round for MagForce USA, Inc. under the lead of …

Posted on by

DGAP-News: MagForce AG / Key word(s): Private Equity MagForce AG: Successful final closing of a growth financing round for MagForce USA, Inc. under the lead of Mithril Capital Management

08.08.2014 / 14:00

---------------------------------------------------------------------

MagForce AG: Successful final closing of a growth financing round for MagForce USA, Inc. under the lead of Mithril Capital Management

Berlin, Germany, August 8th, 2014 - MagForce AG (Frankfurt, Entry Standard, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, today announced that its subsidiary MagForce USA, Inc. has successfully closed its growth financing round. Mithril Capital Management, a growth-stage technology fund founded by Ajay Royan and Peter Thiel, led a group of strategic investors including the management in financing MagForce USA's growth round with proceeds of USD 15 million, with an option to increase the size of the round to USD 30 million. MagForce AG owns 77% of MagForce USA as of this closing. The strategic investors presently hold 23% of MagForce USA and may increase their ownership in future by exercising the warrants held by them. After all warrants are exercised, MagForce AG will continue to retain a majority ownership position in MagForce USA.

MagForce USA, Inc., has been granted a license by MagForce AG for the development and commercialization of NanoTherm(TM) Therapy for the treatment of brain and prostate cancers and will be responsible for developing the North American market (US, Mexico and Canada) for MagForce's technology and products. Under the prostate cancer license, MagForce USA will also receive royalties for the sale of NanoTherm(TM) particles for the treatment of prostate cancer outside North America.

Ben J. Lipps, Chairman and CEO of MagForce AG and also of MagForce USA, Inc., commented: "I am very optimistic about the US market, which has the largest potential especially for prostate cancer treatment. MagForce USA aims at developing its technology to offer a new focal treatment for Intermediate Stage Prostate Cancer with precise ablation of the cancer lesion while sparing normal tissue. In Mithril, we have found the right collaborator to support our expansion plans. Ajay Royan and Peter Thiel have proven themselves numerous times to be valuable partners in helping companies unlock long-term growth."

Ajay Royan, co-founder and managing general partner of Mithril, said: "Conventional treatments for prostate cancer have significant side effects and other limitations, while patients with glioblastoma currently have few good options at all. That's why MagForce's innovative approach to solid tumors is very promising and potientially important."

About MagForce AG and MagForce USA, Inc. MagForce AG, listed in the entry standard of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group's proprietary NanoTherm(TM) therapy enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles. NanoTherm(TM), NanoPlan(R), and NanoActivator(R) are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG in selected countries. For more information, please visit: http://www.magforce.com. Please learn more: video (You Tube)

About Mithril Capital Management Mithril is a global investment firm that provides capital to leading growth companies by partnering with teams who use technology to build transformative and durable businesses, often in industries long overdue for change. Each of these businesses is unique, but all face common challenges to unlocking long-term growth. Mithril helps navigate these critical inflection points by investing in size and with conviction. For more information, please visit: http://www.mithril.com

View original post here:
DGAP-News: MagForce AG: Successful final closing of a growth financing round for MagForce USA, Inc. under the lead of ...

Researchers to track effects of revolutionary new medicines

Posted on by

PUBLIC RELEASE DATE:

4-Aug-2014

Contact: Jamie Brown jamie.brown@liverpool.ac.uk 44-151-794-2248 University of Liverpool

The University of Liverpool has been awarded 2 million to become a leading centre in the UK for tracking the fate in the body of materials used in breakthrough medicines.

Researchers will be using radioactive labelling to find out where key materials used in nanomedicines go once the medicines have entered the body.

Nanomedicines are a relatively new class of therapy which can deliver small quantities of a drug in a targeted way to the affected part of the body. Unlike traditional therapies, nanomedicines are formulated to use lower quantities, with the potential for cost savings, fewer side-effects and more rapid treatment of disease.

Part of nanomedicine formulations involve the use of polymers or other materials which help the drug reach its target, but until now there has been little research into where the carrier materials accumulate, despite them often making up over half of the mass of the medicine.

The Liverpool Radiomaterials Chemistry Laboratory at the University will 'tag' parts of the medicines by making some of them harmlessly radioactive and then monitor how they move around the body once drugs are administered. The process of making the polymers radioactive won't alter their chemical composition, so the nanomedicines can be studied pre-clinically without changing how they work.

Chemist, Professor Steve Rannard, said: "Nanomedicines have been used widely in cancer treatment where side-effects are often weighed against the short time span of treatment and the urgency of the condition.

"However they are now being increasingly studied for chronic conditions where treatment can go on for decades. This raises questions about where materials go and how they leave the body during long-term exposure."

Go here to read the rest:
Researchers to track effects of revolutionary new medicines

In the Quest to Treat Intracerebral Hemorrhage, Nanomaterials Show Promise

Posted on by

Contact Information

Available for logged-in reporters only

Newswise Intracerebral hemorrhage is a type of stroke that affects two million people worldwide each year. Despite its seriousness, no effective treatment has yet been developed. But if a recent study in the journal Nanomedicine is right, good news for doctors and patients might one day arrive in a very small package: namely, a peptide nanofiber scaffold. In the last few decades, molecular engineering of various self-assembling peptide nanofiber scaffolds (SAPNS) has emerged as an active area of research. The peptide can form stable structures that self-assemble into a gel-like substance.

Now a University of Hong Kong team led by Professor Raymond Tak Fai Cheung, PhD and his student Lynn Yan-Hua Sang, PhD, who performed the majority of the experimental work, suggests a new therapeutic strategy for intracerebral hemorrhage: injecting SAPNS directly into a hemorrhagic lesion. Using rats, the team found that SAPNS attenuated brain injury, reduced brain cavity volume and enhanced recovery of brain function. This is the first time a nanomaterial has been used to replace the hematoma in the deep brain in a rat model of intracerebral hemorrhage. The hemostatic effects of SAPNS and other self-assembling peptides were discovered by co-author Rutledge G. Ellis-Behnke, PhD, who advised Drs. Cheung and Sang.

One man with a keen interest in this result is Terrence W. Norchi, President and CEO of Arch Therapeutics, a Wellesley, MA-based medical device company that is exploring a potential alternative approach to traditional stasis and barrier applications, including stopping bleeding during surgery, after trauma and other applications. Arch Therapeutics is also the worldwide exclusive licensee of intellectual property owned by the Massachusetts Institute of Technology (MIT) and the University of Hong Kong (UHK), in which the composition of SAPNS is a cited agent for stopping bleeding. Dr. Ellis-Behnke, who performed his groundbreaking hemostasis research at MIT and UHK, is a co-founder of Arch Therapeutics.

Archs AC5 Surgical Hemostatic Device, currently in preclinical development, is also a peptide nanofiber scaffoldone that is being designed to achieve hemostasis in laparoscopic and open surgical procedures. It represents a new approach to the rapid cessation of bleeding and control of fluid leakage during surgery and trauma care. The time to hemostasis with this approach is measured typically in 15 to 30 seconds rather than several minutes as with existing solutions. It is also being designed to conform to irregular wound geometry, to allow for normal healing and to help maintain a clear field of vision in the wound area during the surgical procedure.

Because it is transparent and neither sticky nor glue-like, evidence supports that AC5 can be used in the laparoscopic or minimally invasive surgical setting. It consists of a synthetic peptide comprising naturally occurring amino acids that are not sourced from animals. When squirted or sprayed onto a wound, the clear, transparent liquid promptly intercalates into the nooks and crannies of the connective tissue where it self-assembles itself into a lattice-like gela physical structure that provides a barrier to leaking substances. It is being designed to quickly stop bleeding with rapid onset of hemostasis, and might also allow surgeons to safely operate through the resulting protective barrier. During the healing process, data supports that the underlying peptide is broken down into its constituent amino acids, then absorbed and either used in the amino acid pool of the body to build protein and muscle, or excreted in the urine.

Advances such as these point toward a future in which self-assembling peptides are a key tool for addressing some of the challenges faced by surgeons today.

Read more here:
In the Quest to Treat Intracerebral Hemorrhage, Nanomaterials Show Promise

Shelton firms products in the pipeline could end diseases

Posted on by

A company specializing in the emerging field of nanomedicine has opened in Shelton, offering the possibility that major healthcare advances could be developed in the city.

U.S. Rep. Jim Himes cuts the ribbon at the new NanoViricides facility in Shelton while joined by company officials, including President and Chairman Anil R. Diwan, Interim Chief Financial Officer Meeta Vyas and Chief Executive Officer Eugene Seymour.

The products being produced here could very well end diseases such as influenza and dengue fever, U.S. Rep. Jim Himes said at this weeks opening of the NanoViricides Inc. facility on Controls Drive.

This is truly a game changer for humankind, Himes said.

He predicted the companys president and chairman, Anil R. Diwan, could even win the Nobel Prize in medicine if products now in development at NanoViricides succeed.

Diwan said the firm has six medicines in the pipeline that would treat the flu, dengue, HIV, herpes (cold sores) and eye viruses.

With money raised from investors, NanoViricides has bought the 18,000-square-foot building at 1 Controls Drive, near Long Hill Cross Road. The company is now moving its facilities and employees there from West Haven.

The Shelton site will include manufacturing areas, labs, research-and-development space and offices. The building offers a lot of room for expansion.

It will be the only nanomedicine clinical product manufacturing facility in Connecticut.

Read more from the original source:
Shelton firms products in the pipeline could end diseases

Nanobiotix revenue for the 2nd quarter of 2014

Posted on by

RegulatoryNews:

NANOBIOTIX (Paris:NANO) (Euronext: NANO ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announces its revenue for the second quarter of 2014.

Income statement

Of which :

License Services

45,847 2,749

91,190 2,749

45,847 2,722

Activity

The revenue recorded by NANOBIOTIX during the second quarter of 2014 relates to the upfront payment (pro-rata share) from the Taiwan-based PharmaEngine within the framework of the licensing contract. This licensing contract was signed in August 2012 for the development and commercialization of Nanobiotixs lead product, NBTXR3 in the Asia-Pacific region. It is distributed using the straight-line method across the period between the date the contract was signed and the scheduled marketing launch in the region. This upfront payment totaled 810,640, generating a product of 45,847 for the period and totalling 91,190 for the first semester in 2014. The invoicing of services totalled 2,749 for the second quarter of 2014. In total, revenue for the second quarter amounts 48,596. Revenue for the first half of 2014 is 93,939 which is fully in line with Company expectations.

Here is the original post:
Nanobiotix revenue for the 2nd quarter of 2014

Global Nanomedicine Market Projected to be Worth USD 177.60 billion by 2019

Posted on by

Albany, New York (PRWEB) July 04, 2014

The new title on Nanomedicine Market (Neurology, Cardiovascular, Anti-inflammatory, Anti-infective, and Oncology Applications) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019," predicts that the total nanomedicine market globally will be worth USD 177.60 billion by 2019, growing considerably from its 2012 value of USD 78.54 billion. This market is expected to achieve a compounded annual growth rate of 12.3% between 2013 and 2019.

Browse Nanomedicine Market Research Report with full TOC: http://www.transparencymarketresearch.com/nanomedicine-market.html.

The report talks about the major growth areas of within the nanomedicine market over the period of forecast. The introduction of new technologies and applications in this sector will propel growth to a significant degree at the global level. Further, the initiatives taken by various governments as well as privately-funded institutions towards promoting the commercialization of new nanomedicine products will boost this market. The report also dwells on the role played by the rising geriatric population base, the prevalence of medical needs that are in need of treatment, as well as the rising incidence of chronic diseases globally.

Make and inquiry: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1753.

According to the report, the leading application segment within the nanomedicine market was that of oncology, holding a 38% share of the overall market in 2012, as a vast number of commercially available products prevail in this sector. The development of nanomedicine-based treatments and products that are able to directly target tumors in the brain and other bodily sites is poised to be a significant factor affecting growth in this market.

Though the largest market segment within the nanomedicine market is that of oncology, the fastest growing segment is the cardiovascular market. According to the Transparency Market Research report, growth in this segment has been fuelled by the presence of a sizeable patient population, and a simultaneous growth in the demand for device and drugs that are based on nanomedicine. These factors are collectively anticipated to further fuel the growth of the cardiovascular segment within the nanomedicine market.

Request for customization for this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1753.

The report also carries out an in-depth analysis of the regional market share based on the applications, revenue, and products. According to the report, the nanomedicine market was largely dominated by North America in 2012. It is expected that this regional market will continue to hold its leading position in the way over the forecast period until 2019. Though the larger market share will be held by North America, it is anticipated that the fastest growing market, by region, will be Asia-Pacific. The report states that the CAGR recorded by the Asia-Pacific market will be 14.6% between 2013 and 2019.

Furthermore, the analysis of the regional markets also concludes that the Europe region is predicted to show a growth rate thats relatively higher than that of North America. Factors that are likely to cause this increased growth rate include: an improvement in the regulatory framework as well as the presence of a wide-ranging product portfolio in the pipeline, set to be introduced by leading market players.

Follow this link:
Global Nanomedicine Market Projected to be Worth USD 177.60 billion by 2019

Scientists engineer nanoparticles to prevent bone cancer, strengthen bones

Posted on by

PUBLIC RELEASE DATE:

30-Jun-2014

Contact: Marjorie Montemayor-Quellenberg mmontemayor-quellenberg@partners.org 617-534-6383 Brigham and Women's Hospital

Boston, MA A research collaboration between Brigham and Women's Hospital (BWH) and Dana-Farber Cancer Institute (DFCI) has utilized nanomedicine technologies to develop a drug-delivery system that can precisely target and attack cancer cells in the bone, as well as increase bone strength and volume to prevent bone cancer progression.

The study is published the week of June 30, 2014 in Proceedings of the National Academy of Sciences.

"Bone is a favorable microenvironment for the growth of cancer cells that migrate from tumors in distant organs of the body, such as breast, prostate and blood, during disease progression," said Archana Swami, PhD, BWH Laboratory of Nanomedicine and Biomaterials, co-lead study author. "We engineered and tested a bone-targeted nanoparticle system to selectively target the bone microenvironment and release a therapeutic drug in a spatiotemporally controlled manner, leading to bone microenvironment remodeling and prevention of disease progression."

"There are limited treatment options for bone cancers," added Michaela Reagan, PhD, DFCI Center for Hematologic Oncology, co-lead study author. "Our engineered targeted therapies manipulate the tumor cells in the bone and the surrounding microenvironment to effectively prevent cancer from spreading in bone with minimal off-target effects."

The scientists developed stealth nanoparticles made of a combination of clinically validated biodegradable polymers and alendronate, a clinically validated therapeutic agent, which belongs to the bisphosphonate class of drugs. Bisphosphonates bind to calcium. The largest store of calcium in the human body is in bones, so bisphosphonates accumulate in high concentration in bones.

By decorating the surface of the nanoparticles with alendronate, the nanoparticles could home to bone tissue to deliver drugs that are encapsulated within the nanoparticles and kill tumor cells, as well as stimulate healthy bone tissue growth. Furthermore, bisphosphonates are commonly utilized during the treatment course of cancers with bone metastasis, and thus alendronate plays a dual role in the context of these targeted nanoparticles.

The scientists tested their drug-toting nanoparticles in mice with multiple myeloma, a type of bone cancer. The mice were first pre-treated with nanoparticles loaded with the anti-cancer drug, bortezomib, before being injected with myeloma cells. The treatment resulted in slower myeloma growth and prolonged survival. Moreover, the researchers also observed that bortezomib, as a pre-treatment regimen, changed the make-up of bone, enhancing its strength and volume.

Here is the original post:
Scientists engineer nanoparticles to prevent bone cancer, strengthen bones

Global Nanomedicine Market: Industry Analysis, Size, Share,Growth, Trends, and Forecast 2013 – 2019

Posted on by

Albany, New York (PRWEB) June 30, 2014

This report includes market estimations for nanomedicine market for the forecast period 2013 2019. The nanomedicine market size is represented in terms of USD billion, and the market estimates and forecasts are calculated considering 2012 as the base year. Moreover, the trends and recent developments of the nanomedicine market have been kept into account while forecasting the market growth and revenue for the period 2013 2019.

Browse the full Nanomedicine Market Report: http://www.transparencymarketresearch.com/nanomedicine-market.html

The overall nanomedicine market is segmented on the basis of applications and geography, and the market estimations for each of these segments, in terms of USD billion, is provided in this report.

The nanomedicine market, on the basis of applications, is segmented into neurological, cardiovascular, oncology, anti-inflammatory, anti-infective and other markets. The nanomedicine market is also estimated and analyzed on the basis of geographic regions such as North America, Europe, Asia-Pacific and the rest of the world. The global trends such as drivers, restraints, and opportunities of the global nanomedicine market is detailed in the market overview chapter of this report, with a view on impact of these factors on market growth along the course of the forecast period.

For further inquiries, ask here: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1753

The chapter on competitive landscape consists of heat map analysis of the key players operating in the global nanomedicine market. Some of the key players of this market include GE Healthcare, Mallinckrodt plc, Nanosphere Inc., Pfizer Inc., Merck & Co Inc., Celgene Corporation, CombiMatrix Corporation, Abbott Laboratories and others. The role of these market players in the global nanomedicine market is analyzed by profiling them on the basis of attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments.

The global nanomedicine market is categorized into the following segments:

Nanomedicine Market by Application

Nanomedicine Market by Geography

Read the original post:
Global Nanomedicine Market: Industry Analysis, Size, Share,Growth, Trends, and Forecast 2013 - 2019


  1. Nanomedicine